International Myotonic Dystrophy Consortium 2022 (IDMC-13)

Back

Repeat Dosing With DYNE-101 is Well Tolerated and Leads to a Sustained Reduction of DMPK RNA Expression in key Muscles for DM1 Pathology in hTfR1/DMSXL Mice and NHPs (presentation)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.